News Focus
News Focus
icon url

brooktrail1933

03/06/24 6:42 PM

#676870 RE: iwasadiver #676858

He said his tumor was in the temporal lobe. And that when they removed the "abscess" they found GBM. I've never heard of a brain abscess related to an infected upper tooth somehow finding its way to the temporal lobe. The ones I've seen related to sinus disease were all arising from a frontal sinusitis. Not aware of a neurovascular pathway from the maxillary sinus to the temporal lobe.

Bottom line - this guy is a fraud, reading off a card in a boiler room somewhere. Hired by a hedge fund or helmet company, or maybe related to the rad-oncs in the UK who were unhappy with the trial results and complained to the journals. IMO.
icon url

Nemesis18

03/06/24 8:09 PM

#676876 RE: iwasadiver #676858

Firstly, you should be applauded for your enquiring mind, for it is from only such debate that truly meaningful advancements are made in the Neuro scientific community.
Well, certainly from where we were 10-20 years ago.
I for one fully support the individual genomic profiling of each patient’s tumour, then adapting the treatment to match that dna signature.
The cure for GBM4 will never come from an ‘outside in approach’, such is the case with DCVAX.

Anyway, for the intellectually curious, I show my brain abscess in my right temporal lobe.

https://investorshub.advfn.com/uimage/uploads/2024/3/6/yltjlF0115E8F-038C-4529-B419-D60D114B47BC.jpeg

Isn’t this more interesting than just waiting for a 2 cent rise in stock price ?
icon url

biosectinvestor

03/07/24 4:13 AM

#676908 RE: iwasadiver #676858

He did not even get into the trial. The first post was a confused complaint about his not getting into the trial despite his “favorable” diagnosis. He’s a confused, nonsensical poster but I agree that he comes off as someone with a crazy story trying to either gain fake fame, someone perhaps with issues, OR hired by someone to create false impressions here.

It is doubtful that any regulator would be “interviewing” him about any clinical trial.